I've been hoping for a large Lyme GWAS study [equivalent to Chris Ponting's ME/CFS GWAS study] --- so your post made me think xmas had come early for me!
@Simon M maybe better to look for (further - Europe ---) large ME/CFS GWAS studies but I've wondered if a Lyme study would actually give the ME/CFS community more useful genetic information and the Lyme community might be well placed to get the funding. Sow the thought/seed?
This study relates to gene expression which is different to GWAS. Actually it reminds me of Alain Moreau's corresponding work on gene expression in ME/CFS. It's consequence/downstream effect i.e. if you've an infection then:
- any lingering virus will be directly changing your gene expression, to make viral proteins; and
- your immune system will have been ramped up to deal with the virus/bacteria --- and any lingering virus/bacteria;
- EDIT - PTLD changes in gene expression are, I assume, what they're focused on (post acute infection).
GWAS looks at the actual gene's [primary/hardwiring] - what predisposes you/protects you - so if a pathway predisposes you then that may be a common pathway --- with potential drug targets --- some drugs may even be approved for other diseases --- (quickly) repurposed for ME/CFS.
There have been useful GWAS studies in diseases with a diagnostic test e.g. diabetes, (high) blood pressure ---. So, if this produced a post infection diagnostic test, for Lyme - PTLD, then a GWAS study on that population might identify the pathway, potential drug targets/treatments.
I've no training in this stuff --- so don't assume what I've posted is accurate!
"
Summary
Lyme disease (LD) is tick-borne disease whose post-treatment sequelae are not well understood. For this study, we enrolled 152 individuals with symptoms of post-treatment LD (PTLD) to profile their peripheral blood mononuclear cells (PBMCs) with RNA sequencing (RNA-seq). Combined with RNA-seq data from 72 individuals with acute LD and 44 uninfected controls, we investigated differences in differential gene expression. We observe that most individuals with PTLD have an inflammatory signature that is distinguished from the acute LD group. By distilling gene sets from this study with gene sets from other sources, we identify a subset of genes that are highly expressed in the cohorts but are not already established as biomarkers for inflammatory response or other viral or bacterial infections. We further reduce this gene set by feature importance to establish an mRNA biomarker set capable of distinguishing healthy individuals from those with acute LD or PTLD as a candidate for translation into an LD diagnostic.